Suppliers and packagers for generic pharmaceutical drug: SUMATRIPTAN SUCCINATE

SUMATRIPTAN SUCCINATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaxosmithkline	IMITREX	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0478-00	2 SYRINGE in 1 CARTON (0173-0478-00) / .5 mL in 1 SYRINGE	1997-01-27
Glaxosmithkline	IMITREX	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0479-00	2 SYRINGE in 1 PACKAGE (0173-0479-00) / .5 mL in 1 SYRINGE	1997-01-23
Glaxosmithkline	IMITREX	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0739-00	2 SYRINGE in 1 PACKAGE (0173-0739-00) / .5 mL in 1 SYRINGE	2006-04-06
Glaxosmithkline	IMITREX	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0739-02	2 SYRINGE in 1 CARTON (0173-0739-02) / .5 mL in 1 SYRINGE	2006-04-06
Glaxosmithkline	IMITREX STATDOSE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0478-00	2 SYRINGE in 1 CARTON (0173-0478-00) / .5 mL in 1 SYRINGE	1997-01-27
Glaxosmithkline	IMITREX STATDOSE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0479-00	2 SYRINGE in 1 PACKAGE (0173-0479-00) / .5 mL in 1 SYRINGE	1997-01-23
Glaxosmithkline	IMITREX STATDOSE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080	NDA	GlaxoSmithKline LLC	0173-0739-00	2 SYRINGE in 1 PACKAGE (0173-0739-00) / .5 mL in 1 SYRINGE	2006-04-06

Sumatriptan Succinate Drug Substance Suppliers: Market Landscape and Patent Analysis

Last updated: February 19, 2026

This report analyzes the current landscape of suppliers for sumatriptan succinate drug substance, focusing on key players, patent expirations, and potential market shifts. The analysis targets pharmaceutical companies and investors evaluating R&D pipelines and investment opportunities in the migraine therapeutics market.

Who Are the Leading Manufacturers of Sumatriptan Succinate Drug Substance?

The production of sumatriptan succinate drug substance is concentrated among a cohort of global manufacturers, primarily located in India and China. These suppliers cater to both generic drug manufacturers and, in some instances, contract manufacturing organizations (CMOs) for branded formulations.

• Key Suppliers:
  • Indian Manufacturers: IOL Chemicals and Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals, and Divi's Laboratories are established players in the API manufacturing sector and are known to produce sumatriptan succinate.
  • Chinese Manufacturers: Several Chinese chemical and pharmaceutical companies are also active in the market, although specific entity names and market share data can be more fluid and less publicly disclosed compared to their Indian counterparts. Examples include Zhejiang Huahai Pharmaceutical Co., Ltd. and Lianyungang Oriental Pharmaceutical Co., Ltd.
  • European and North American Presence: While less dominant in sheer volume for generic API supply, some Western-based CMOs may offer sumatriptan succinate production capabilities, often focusing on higher-value, specialized manufacturing or as part of integrated drug product development services.

The market is characterized by a significant number of suppliers, leading to competitive pricing for the drug substance. This competition is driven by the expiration of primary patents for sumatriptan and the subsequent rise of generic drug production.

What Are the Key Patents Governing Sumatriptan Succinate and Their Expiration Dates?

The foundational patents for sumatriptan, specifically the molecule and its therapeutic use, have long expired. However, patents related to specific crystalline forms, manufacturing processes, and formulations can still influence market dynamics.

• Original Composition of Matter Patents: The primary patents covering the sumatriptan molecule, originally held by GlaxoSmithKline (GSK), expired globally in the early 2000s. For instance, U.S. Patent 4,939,178, concerning novel indole derivatives including sumatriptan, expired in 2007 [1]. European Patent EP0145079B1, related to the same inventive class, also expired around the same period.

• Process Patents: Numerous patents have been filed and granted over the years concerning improved or novel methods for synthesizing sumatriptan succinate. These patents aim to enhance yield, purity, or cost-effectiveness. Examples include patents describing specific reaction conditions, purification techniques, or polymorphic forms.

  • Example of a process patent focus: U.S. Patent 7,199,247 B2, titled "Process for the preparation of sumatriptan succinate," was granted in 2007 and its term would extend to 2025, considering patent term extension. Such patents can still provide a degree of protection for specific manufacturing routes, requiring generic API manufacturers to develop non-infringing processes.

• Polymorph Patents: Crystalline forms (polymorphs) of active pharmaceutical ingredients (APIs) can have different physical properties, such as solubility and stability, impacting bioavailability. Patents covering specific, therapeutically advantageous polymorphs can extend market exclusivity.

  • While specific widely-cited polymorph patents for sumatriptan succinate are less prevalent in public domain literature post-initial patent expiry compared to some other blockbuster drugs, it remains a potential area for patent protection. Generic manufacturers must ensure their manufactured API does not infringe on any existing polymorph patents.

• Formulation Patents: Patents related to specific dosage forms, such as nasal sprays, injectables, or orally disintegrating tablets, and their unique delivery mechanisms, can also impact the market. For example, patents related to the formulation of sumatriptan in a fast-dissolving tablet might have later expiration dates than the base molecule patent.

The expiration of key patents has democratized the production of sumatriptan succinate, leading to a highly competitive generic API market. However, any API supplier must conduct thorough freedom-to-operate (FTO) analyses to ensure their manufacturing processes and the physical form of the API do not infringe upon any remaining valid patents.

What Are the Regulatory Requirements for Sumatriptan Succinate API Manufacturers?

Manufacturers of sumatriptan succinate drug substance must adhere to stringent regulatory standards to ensure product quality, safety, and efficacy. These requirements are overseen by global regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory authorities.

• Good Manufacturing Practices (GMP): All API manufacturers must operate under current Good Manufacturing Practices (cGMP). This involves rigorous control over all aspects of production, including personnel, facilities, equipment, raw material sourcing, manufacturing processes, quality control, documentation, and distribution.

  • FDA GMP Compliance: Facilities supplying to the U.S. market are subject to FDA inspections and must demonstrate compliance with 21 CFR Part 210 and 211.
  • EMA GMP Compliance: For the European market, manufacturers must comply with EudraLex Volume 4.

• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF is a submission to regulatory authorities containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.

  • U.S. DMFs: Submitted to the FDA, these allow drug product manufacturers to reference the API information without having direct access to it.
  • European CEPs (Certificates of Suitability): The European Directorate for the Quality of Medicines & HealthCare (EDQM) issues Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP certifies that the quality of a substance is suitably controlled by the relevant monograph of the European Pharmacopoeia.

• Pharmacopoeial Compliance: The sumatriptan succinate API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define tests for identity, purity (including limits for specific impurities and residual solvents), assay, and other critical quality attributes.

• Impurity Profiling: Regulatory agencies require detailed impurity profiling. Manufacturers must identify, quantify, and control process-related impurities and degradation products. Limits for genotoxic impurities are particularly stringent. For sumatriptan succinate, common impurities might arise from side reactions during synthesis or degradation of the molecule.

• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines is essential. Key guidelines include:

  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q3A/B/C/D: Impurities in New Drug Substances, New Drug Products, Residual Solvents, and Elemental Impurities, respectively.
  • ICH Q11: Development and Manufacture of Drug Substances.

Regulatory compliance is a significant barrier to entry and a critical factor for sustained supply. Manufacturers with strong regulatory track records and established DMFs or CEPs are generally preferred by pharmaceutical companies.

What Are the Key Market Trends Affecting Sumatriptan Succinate Supply?

The sumatriptan succinate market is mature and primarily driven by generic competition. Key trends include:

• Price Erosion: With multiple suppliers and expired patents, the price of sumatriptan succinate API has experienced significant erosion. This puts pressure on manufacturers to optimize their production costs.

• Consolidation and Supply Chain Reliability: While competition is high, there is a persistent need for reliable, high-quality suppliers. Pharmaceutical companies increasingly value supply chain security and may favor larger, more established manufacturers with robust quality systems and diversified manufacturing sites. This can lead to some consolidation or strategic partnerships.

• Emerging Markets: While Western markets are mature, there is ongoing demand and growth in emerging markets as access to healthcare and essential medicines improves. Indian and Chinese manufacturers are well-positioned to serve these regions.

• Focus on Cost Efficiency and Process Innovation: Manufacturers are continuously seeking ways to reduce manufacturing costs through process optimization, yield improvement, and solvent recovery. Innovation in green chemistry and sustainable manufacturing practices is also gaining traction.

• Geopolitical and Supply Chain Risks: Recent global events have highlighted the vulnerabilities in pharmaceutical supply chains. Companies are increasingly looking to diversify their supplier base and may favor domestic or near-shore manufacturing for critical APIs, although this is more challenging for established generic products like sumatriptan succinate where cost is paramount.

• Competition from Newer Migraine Therapies: While sumatriptan remains a cornerstone of acute migraine treatment, the market is evolving with the introduction of newer drug classes such as gepants (e.g., ubrogepant, rimegepant) and ditans (e.g., lasmiditan). These newer therapies, while often more expensive, may capture market share for patients who do not respond adequately to or tolerate triptans, potentially impacting overall demand for sumatriptan succinate over the long term.

Key Takeaways

• The sumatriptan succinate drug substance market is dominated by Indian and Chinese manufacturers, driven by the expiration of primary patents.
• While composition of matter patents have expired, manufacturers must navigate remaining process and potential polymorph patents to ensure freedom to operate.
• Strict adherence to cGMP, pharmacopoeial standards, and ICH guidelines is mandatory for all API suppliers. Regulatory filings like DMFs and CEPs are critical for market access.
• The market is characterized by intense price competition, a focus on cost efficiency, and a growing emphasis on supply chain reliability.
• Emerging competition from newer migraine treatment classes may influence long-term demand for sumatriptan succinate.

Frequently Asked Questions

1. Which regulatory bodies are most critical for sumatriptan succinate API suppliers targeting the US and European markets?

The U.S. Food and Drug Administration (FDA) for the U.S. market and the European Medicines Agency (EMA) for the European market are the primary regulatory bodies. Manufacturers must also comply with guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

2. What is the typical shelf life for sumatriptan succinate drug substance?

The typical shelf life for sumatriptan succinate drug substance, when stored under recommended conditions (e.g., protected from light and moisture at controlled room temperature), is generally between two to five years. Specific stability data is proprietary to each manufacturer and detailed in their regulatory filings.

3. How does the purity profile of sumatriptan succinate API affect its marketability?

Purity is a critical determinant of marketability. Regulatory agencies mandate strict limits for impurities, including related substances, residual solvents, and elemental impurities. API suppliers with robust impurity control strategies and documented adherence to ICH guidelines (e.g., ICH Q3A/B/C/D) are more competitive and command better pricing.

4. Are there significant regional differences in the quality standards or specifications for sumatriptan succinate API?

While major pharmacopoeias like the USP and Ph. Eur. set global benchmarks, minor regional variations in testing methodologies or specific impurity limits can exist. However, for globally marketed APIs like sumatriptan succinate, manufacturers typically aim to meet the most stringent requirements (e.g., USP and Ph. Eur. monographs) to ensure broad market access.

5. What is the average lead time for procuring a significant quantity (e.g., multi-ton lot) of sumatriptan succinate drug substance from established suppliers?

The average lead time for multi-ton quantities of sumatriptan succinate drug substance from established suppliers typically ranges from 8 to 16 weeks. This period accounts for production scheduling, batch manufacturing, quality control testing, and release. However, this can vary based on the supplier's current capacity, order volume, and existing inventory levels.

Citations

[1] U.S. Patent 4,939,178. (1989). Novel indole derivatives. Assigned to The Wellcome Foundation Limited.